TITLE

Palliative higher-dose radiation improved overall survival in NSCLC

PUB. DATE
October 2008
SOURCE
Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p29
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses a study which showed improvement in the overall survival rate of patients with non-small cell lung cancer who were treated with higher-dose palliative thoracic radiation. Results for symptom palliation, overall survival, toxicity and re-irradiation rate were evaluated in the study. It also indicated the percentage of patients in the high-dose and low-dose groups who were still alive at one year and after two years.
ACCESSION #
34781551

 

Related Articles

  • Application of adenosine 5'-triphosphate (ATP) infusions in palliative home care: design of a randomized clinical trial. Beijer, Sandra; van Rossum, Erik; Hupperets, Pierre S.; Spreeuwenberg, Cor; van den Beuken, Marieke; Winkens, Ron A.; Ars, Lisette; van den Borne, Ben E.; de Graeff, Alexander; Dagnelie, Pieter C. // BMC Public Health;2007, Vol. 7 Issue 1, p4 

    Background: Palliative care in cancer aims at alleviating the suffering of patients. A previous study in patients with advanced non-small-cell lung cancer showed that adenosine 5′-triphosphate (ATP) infusions had a favourable effect on fatigue, appetite, body weight, muscle strength,...

  • A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Besse, B.; Heist, R. S.; Papadmitrakopoulou, V. A.; Camidge, D. R.; Beck, J. T.; Schmid, P.; Mulatero, C.; Miller, N.; Dimitrijevic, S.; Urva, S.; Pylvaenaeinen, I.; Petrovic, K.; Johnson, B. E. // Annals of Oncology;Feb2014, Vol. 25 Issue 2, p505 

    Everolimus 2.5 mg/day plus granulocyte colony-stimulating factor was identified as the feasible dose given with standard-dose cisplatin–etoposide for treatment-naive extensive-stage small-cell lung cancer (SCLC). Based on the results of this study and a study of everolimus monotherapy for...

  • Non-small cell lung cancer therapy: safety and efficacy in the elderly. Glotzer, Owen S.; Fabian, Thomas; Chandra, Anurag; Bakhos, Charles T. // Drug, Healthcare & Patient Safety;Apr2013, Vol. 5, p113 

    Background: Our objective was to evaluate and review the current literature on the treatment of non-small cell lung cancer (NSCLC) in the elderly. Methods: We selected recent peer-reviewed articles addressing ageing, cancer treatment in the elderly, and lung cancer treatment in the elderly. We...

  • An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. R. de Boer; Y. Humblet; J. Wolf; L. Nogová; K. Ruffert; T. Milenkova; R. Smith; A. Godwood; J. Vansteenkiste // Annals of Oncology;Mar2009, Vol. 20 Issue 3, p486 

    Background: Vandetanib (ZACTIMA™; ZD6474) is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. The safety and tolerability of vandetanib plus pemetrexed was assessed in patients with advanced non-small-cell...

  • Treatment of advanced non small cell lung cancer. Bareschino, Maria Anna; Schettino, Clorinda; Rossi, Antonio; Maione, Paolo; Sacco, Paola Claudia; Zeppa, Rosario; Gridelli, Cesare // Journal of Thoracic Disease;Jun2011, Vol. 3 Issue 2, p122 

    Lung cancer is the major cause of cancer death in the world. Non Small Cell Lung Cancer (NSCLC) accounts approximately 80-85% of all lung cancer diagnosis; the majority of patients will be diagnosed with non operable, advanced-stage disease. Palliative chemotherapy and/or radiotherapy represent...

  • The mathematician versus the malignancy. Dolgin, Elie // Nature Medicine;May2014, Vol. 20 Issue 5, p460 

    The article focuses on Franziska Michor, mathematical biologist at the Dana-Farber Cancer Institute in Boston, Massachusetts, who used a mathematical formula, continuous-time Markov chain to model cell birth and death dynamics, for maximum tolerated dose and dose schedule of Tarceva for...

  • Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. Xenidis, Nikolaos; Vardakis, Nikolaos; Varthalitis, Ioannis; Giassas, Stylianos; Kontopodis, Emmanouel; Ziras, Nikolaos; Gioulbasanis, Ioannis; Samonis, George; Kalbakis, Kostas; Georgoulias, Vassilis // Cancer Chemotherapy & Pharmacology;Jul2011, Vol. 68 Issue 1, p63 

    Purpose: To evaluate efficacy and toxicity of a combination of pegylated liposomal doxorubicin and irinotecan in patients with refractory small-cell lung cancer. Patients and methods: Thirty-one patients with early relapse after first-line therapy with cisplatin/etoposide were treated with...

  • gefitinib.  // Davis's Drug Guide for Nurses, 9th edition;2005, p470 

    Presents information on gefitinib, an antinoeplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer in patients who have not responded to platinum or docetaxel-based chemotherapy. Pharmacokinetics; Contraindications and precautions; Adverse reactions...

  • Factors Driving the Choice of the Best Second-Line Treatment of Advanced NSCLC. Maione, Paolo; Rossi, Antonio; Bareschino, Maria Anna; Sacco, Paola Claudia; Schettino, Clorinda; Falanga, Marzia; Barbato, Valentina; Ambrosio, Rita; Gridelli, Cesare // Reviews on Recent Clinical Trials;Jan2011, Vol. 6 Issue 1, p44 

    Platinum-based chemotherapy, with or without the antiangiogenetic drug bevacizumab, is the standard first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib has been recently approved as...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics